Kailera Therapeutics (KLRA) is One of the Best IPO Stocks with Huge Upside Potential

Kailera Therapeutics Inc. (NASDAQ:KLRA) is one of the best IPO stocks with huge upside potential. On July 7, Kailera Therapeutics announced positive topline results from two Phase 3 clinical trials conducted by Hengrui Pharma for HRS-7535/KAI-7535, an oral small-molecule GLP-1 receptor agonist. In the obesity trial, participants achieved a mean weight loss of up to 10.9% by Week 44 and 11.1% by Week 50, while the type 2 diabetes trial demonstrated a mean HbA1c reduction of 1.50% to 1.68%.

Liver safety findings across both trials remained consistent with prior data, showing no observed safety signals. These results underscore the potential for the oral treatment to offer a convenient and scalable alternative for patients, maintaining efficacy while providing a favorable safety profile.

Kailera Therapeutics (KLRA) is One of the Best IPO Stocks with Huge Upside Potential

Concurrent with these developments, Kailera Therapeutics Inc. (NASDAQ:KLRA) is advancing KAI-7535 through a global Phase 2 clinical trial that began in April 2026. This study aims to further optimize the drug’s clinical profile for obesity treatment by assessing a broad range of doses and titration strategies, with results expected in 2027.

Kailera Therapeutics Inc. (NASDAQ:KLRA) is a clinical-stage biotechnology company dedicated to advancing a diversified pipeline of obesity treatments, including four clinical-stage candidates. The company’s portfolio leverages various GLP-1-based mechanisms to provide flexible, effective options for weight management across different stages of a patient’s journey.

While we acknowledge the risk and potential of KLRA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than KLRA and that has 10,000% upside potential, check out our report about the cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1